Clinical trials: in Czechia
Episodic Migraine
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine.
- Trial name
- E-BEOND (NCT06047457)
- Testing
- Botulinum toxin type A
- Where
- 105 sites in United States, Canada and 6 more
- Volunteers
- 751 people
- Sponsor
- Ipsen
Renal Failure, CVVHD
Analysis of Paediatric Treatments With multiFiltratePRO
This clinical study evaluates the performance of the MultifiltratePro in pediatric mode for Continuous Venovenous Hemodiafiltration (CVVHD) in children.
- Trial name
- ECHOped (NCT06603324)
- Testing
- CVVHD treatment in paediatric mode with multiFiltratePRO
- Where
- 2 sites in Czechia, Germany
- Volunteers
- 43 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Chronic Migraine
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine.
- Trial name
- C-BEOND (NCT06047444)
- Testing
- Botulinum toxin type A
- Where
- 120 sites in United States, Canada and 7 more
- Volunteers
- 759 people
- Sponsor
- Ipsen
Menstrual Migraine (MM)
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
A migraine attack is a moderate or severe headache that usually occurs on one side of the head and is often throbbing or pulsating.
- Trial name
- ATO MM (NCT06806293)
- Testing
- Atogepant
- Where
- 95 sites in China, Czechia and 10 more
- Volunteers
- 468 people
- Sponsor
- AbbVie
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukaemia
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than…
- Trial name
- NCT01949129
- Testing
- VP16, TBI, Thiotepa
- Where
- 119 sites in Argentina, Australia and 29 more
- Volunteers
- 1,800 people
- Sponsor
- St. Anna Kinderkrebsforschung
Major Depressive Disorder
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder
- Trial name
- NCT07772531
- Testing
- BMS-986511
- Where
- 27 sites in United States, Czechia
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
Wet Age Related Macular Degeneration, wAMD
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
- Trial name
- wAMD (NCT06683742)
- Testing
- EYP-1901, Aflibercept (2.0 mg)
- Where
- 113 sites in United States, Brazil and 8 more
- Volunteers
- 400 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the…
- Trial name
- FLAURA2 (NCT04035486)
- Testing
- Osimertinib, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin
- Where
- 153 sites in United States, Argentina and 19 more
- Volunteers
- 587 people
- Sponsor
- AstraZeneca
Paroxysmal Nocturnal Hemoglobinuria
A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
This is a 36-month, long-term, multicenter, observational study designed to describe the real world effectiveness of pegcetacoplan in patients with PNH.
- Trial name
- COMPLETE (NCT05776472)
- Testing
- Pegcetacoplan
- Where
- 87 sites in Australia, Belgium and 13 more
- Volunteers
- 165 people
- Sponsor
- Swedish Orphan Biovitrum
Breast Cancer
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab…
- Trial name
- Astefania (NCT04873362)
- Testing
- Atezolizumab, Trastuzumab Emtansine, Trastuzumab
- Where
- 238 sites in United States, Australia and 30 more
- Volunteers
- 1,188 people
- Sponsor
- Hoffmann-La Roche
Geographic Atrophy Secondary to Age-related Macular Degeneration
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
- Trial name
- NCT06990269
- Testing
- ADX-038
- Where
- 83 sites in United States, Australia and 10 more
- Volunteers
- 240 people
- Sponsor
- ADARx Pharmaceuticals, Inc.
Melanoma
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that: is advanced or metastatic (spread to other parts of…
- Trial name
- NCT04657991
- Testing
- Encorafenib, Binimetinib, Pembrolizumab
- Where
- 151 sites in United States, Argentina and 25 more
- Volunteers
- 257 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or…
- Trial name
- CodeBreaK 301 (NCT06252649)
- Testing
- FOLFIRI Regimen, Sotorasib, Panitumumab
- Where
- 291 sites in United States, Argentina and 33 more
- Volunteers
- 450 people
- Sponsor
- Amgen
Heart Failure
First in Human Clinical Investigation of the FIRE1 System in Heart Failure Patients (FUTURE-HF)
First in Human Clinical Investigation of the FIRE1 Device/System to evaluate the feasibility and safety of implanting the FIRE1 system in up to 50 stable HF patients.
- Trial name
- NCT04203576
- Testing
- FIRE1 System
- Where
- 13 sites in Czechia, Georgia and 3 more
- Volunteers
- 50 people
- Sponsor
- Foundry Innovation & Research 1, Limited (FIRE1)
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC).
- Trial name
- NCT04136171
- Testing
- Eplontersen
- Where
- 139 sites in United States, Argentina and 19 more
- Volunteers
- 1,438 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- EMBARK (NCT06883305)
- Testing
- Tezepelumab
- Where
- 305 sites in United States, Brazil and 16 more
- Volunteers
- 990 people
- Sponsor
- AstraZeneca
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Trial name
- MAJIC (NCT05057494)
- Testing
- Acalabrutinib, Venetoclax, Obinutuzumab
- Where
- 37 sites in United States, Australia and 5 more
- Volunteers
- 607 people
- Sponsor
- AstraZeneca
Hidradenitis Suppurativa
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin…
- Trial name
- Intrepid (NCT06468228)
- Testing
- Lutikizumab
- Where
- 279 sites in United States, Argentina and 42 more
- Volunteers
- 1,400 people
- Sponsor
- AbbVie
Lupus Erythematosus, Systemic, Lupus Nephritis
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active…
- Trial name
- NCT06581198
- Testing
- rapcabtagene autoleucel
- Where
- 107 sites in United States, Argentina and 24 more
- Volunteers
- 179 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.